Skip to content

Released Mar 16, 2017, before the open

10-K filed Mar 16, 2017, 75 days after period end · 0001193125-17-084396

Q4 2016 · 10-K
Revenue$47.00K+88.0% vs Q4 2015−2.1% vs Q3 2016
Net Income-$26.94MN/M vs Q4 2015N/M vs Q3 2016
EPS Diluted-$0.65N/M vs Q4 2015N/M vs Q3 2016
Operating Income-$27,165,000N/M
Operating Cash Flowderived-$19,998,000N/M
Free Cash Flowderived-$20,023,000N/M
Margins · derived
Operating margin-57797.9%+59414.1 pt vs Q4 2015
Net margin-57308.5%+58875.5 pt vs Q4 2015

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2016Q4 2015Q4 2014Q4 2013
Revenue$47.00K$25.00K$16.00K$21.00K
Net Income-$26.94M-$29.05M-$25.93M—
EPS Diluted-$0.65-$0.81-$0.79-$0.72

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR